Form4insider filings, from the source

SEC Form 4 · accession 0001140361-17-000855

OncoMed Pharmaceuticals Inc · OMED

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner
John A. Lewicki
Officer — EVP, Research & Development
Period of report
Jan 3, 2017
Accepted (ET)
Jan 5, 2017 · 7:11 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001302573

Table I — non-derivative securities

SecurityDateCodeSharesPriceA/DOwned afterD/INature of ownership
Common StockF2Jan 3, 2017M9,175$1.43A40,811D
Common StockF3,F2Jan 3, 2017S9,175$7.6343D31,636D
Common StockF4holding———84,815ISee Footnote

Table II — derivative securities

SecurityConv. / exercise priceDateCodeSharesA/DExercisableExpiresUnderlyingUnderlying sharesOwned afterD/I
Stock Option (Right to Buy)F5$1.43Jan 3, 2017M9,175D—Jan 11, 2017Common Stock9,1750D
Stock Option (Right to Buy)F6$7.66Jan 3, 2017A65,000A—Jan 2, 2027Common Stock65,00065,000D

Explanation of responses